Viewing data from:

JOBEVNE

Biosimilar

BEVACIZUMAB-NWGD | B761175 | BIOCON BIOLOGICS INC

2 products0 Purple Book patents2 biosimilars

Biologic LOEBiosimilar competition

2 approved biosimilars

April 9, 2037(3933 days remaining)

Regulatory Exclusivities

Type	Expiry	Status	Source
12-Year BPCIA	Apr. 9, 2037	Active	Computed

Purple Book Patents

No listed patents in Purple Book.

Estimated Patent LOE

Jun. 26, 20456933 days remaining

Based on latest discovered patent 12344859(manufacturing) · relevance 68/100

Estimate based on AI-discovered patents. No patents are officially listed in the Purple Book for this product.

Approved Biosimilars

JobevneBLA 761175JobevneBLA 761175

Discovered Patents

View all 198 patents →

Top 50 of 198 AI-discovered patents by relevance.

Composition

(26)

85/1007090834Grant: 2006-08-15 | Exp: 2026-08-10

85/10010696721Grant: 2020-06-30 | Exp: 2040-06-25

85/1007427596Grant: 2008-09-23 | Exp: 2028-09-18

85/1007803576Grant: 2010-09-28 | Exp: 2030-09-23

85/1007449551Grant: 2008-11-11 | Exp: 2028-11-06

75/1009273113Grant: 2016-03-01 | Exp: 2036-02-25

75/1007364731Grant: 2008-04-29 | Exp: 2028-04-24

75/1007700571Grant: 2010-04-20 | Exp: 2030-04-15

75/1006395707Grant: 2002-05-28 | Exp: 2022-05-23

75/10010428125Grant: 2019-10-01 | Exp: 2039-09-26

75/1007973138Grant: 2011-07-05 | Exp: 2031-06-30

75/1007208472Grant: 2007-04-24 | Exp: 2027-04-19

75/10012098213Grant: 2024-09-24 | Exp: 2044-09-19

75/1006407213Grant: 2002-06-18 | Exp: 2022-06-13

75/1007629145Grant: 2009-12-08 | Exp: 2029-12-03

75/1007378507Grant: 2008-05-27 | Exp: 2028-05-22

75/1006528624Grant: 2003-03-04 | Exp: 2023-02-27

72/1008268313Grant: 2012-09-18 | Exp: 2032-09-13

72/10010561737Grant: 2020-02-18 | Exp: 2040-02-13

72/10011111312Grant: 2021-09-07 | Exp: 2041-09-02

70/1007300656Grant: 2007-11-27 | Exp: 2027-11-22

70/1007276586Grant: 2007-10-02 | Exp: 2027-09-27

70/1006242195Grant: 2001-06-05 | Exp: 2021-05-31

70/1006639055Grant: 2003-10-28 | Exp: 2023-10-23

65/10011440971Grant: 2022-09-13 | Exp: 2042-09-08

65/1009284376Grant: 2016-03-15 | Exp: 2036-03-10

Formulation

(3)

75/1008318161Grant: 2012-11-27 | Exp: 2032-11-22

70/1009574005Grant: 2017-02-21 | Exp: 2037-02-16

70/10010188735Grant: 2019-01-29 | Exp: 2039-01-24

Method of Use

(1)

92/1007622115Grant: 2009-11-24 | Exp: 2029-11-19

Manufacturing

(16)

88/1009631007Grant: 2017-04-25 | Exp: 2037-04-20

78/1006270988Grant: 2001-08-07 | Exp: 2021-08-02

75/1009200030Grant: 2015-12-01 | Exp: 2035-11-26

75/10011649262Grant: 2023-05-16 | Exp: 2043-05-11

72/10011680110Grant: 2023-06-20 | Exp: 2043-06-15

72/10012274960Grant: 2025-04-15 | Exp: 2045-04-10

72/10011028149Grant: 2021-06-08 | Exp: 2041-06-03

72/1009150641Grant: 2015-10-06 | Exp: 2035-10-01

72/10011591382Grant: 2023-02-28 | Exp: 2043-02-23

70/10011634836Grant: 2023-04-25 | Exp: 2043-04-20

70/1006656466Grant: 2003-12-02 | Exp: 2023-11-27

70/10010336983Grant: 2019-07-02 | Exp: 2039-06-27

68/10012344859Grant: 2025-07-01 | Exp: 2045-06-26

68/1009422329Grant: 2016-08-23 | Exp: 2036-08-18

65/10010501491Grant: 2019-12-10 | Exp: 2039-12-05

65/1006528286Grant: 2003-03-04 | Exp: 2023-02-27

Device

(1)

68/1009522227Grant: 2016-12-20 | Exp: 2036-12-15

Diagnostic

(3)

88/10010031141Grant: 2018-07-24 | Exp: 2038-07-19

70/10012174184Grant: 2024-12-24 | Exp: 2044-12-19

65/1008227195Grant: 2012-07-24 | Exp: 2032-07-19

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

No clinical trials found on ClinicalTrials.gov for this drug

Purple Book (Biologics)

BLA 761175 | 2 presentations

BiosimilarLicensedCDERInjection

Proper Name

bevacizumab-nwgd

Applicant

Biocon Biologics Inc.

Approval Date

9-Apr-25

Reference Product: Avastin — bevacizumab

Presentations

100MG/4ML (25MG/ML) — Single-Dose Vial (Intravenous)

400MG/16ML (25MG/ML) — Single-Dose Vial (Intravenous)

Source: FDA Purple Book (purplebooksearch.fda.gov).

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
Apr 16, 2025	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (2)

Sort:

#001 — 100MG/4ML

▴

INJECTABLE;INJECTION | Approved: 2025-04-09 00:00:00

No patent or exclusivity listings for this strength.

#002 — 400MG/16ML

▾

INJECTABLE;INJECTION | Approved: 2025-04-09 00:00:00